Kura: KO-539 Shows Preclinical Anti-Tumor Activity In NPM1, DNMT3A Mutant AML

(RTTNews) - Kura Oncology, Inc. (KURA) reported new results for KO-539, the company's selective inhibitor of the menin-MLL protein-protein interaction, which is currently in preclinical development as a potential treatment for patients with genetically-defined subsets of acute leukemias. The new results demonstrate significant activity in preclinical models of additional genetically-defined subsets of AML, including those with oncogenic driver mutations in NPM1, IDH1, IDH2 and DNMT3A.

Yi Liu, Chief Scientific Officer, Kura Oncology, said: "We're encouraged by the results presented today because they demonstrate that menin-MLL inhibitors have the potential to be active in subtypes representing approximately half of the patients with AML and drive robust and persistent responses in preclinical models."